ClinicalTrials.gg
TerminatedNCT04240158Updated Aug 16, 2024

IW-6463 Safety Study in Healthy Elderly Subjects

A Phase 1 interventional study of IW-6463 and Matching Placebo in Other, sponsored by Tisento Therapeutics. Terminated at 1 site in Netherlands. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Tisento Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Some subjects could not complete the second crossover period due to COVID-19-related site closure. The study was closed to allow analysis of all collected data.

From the registry’s dates

  • Primary completion was May 2020, 6 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.

Read the detailed description

Participants will receive up to a total of 30 daily doses of study drug (15 days of daily IW-6463, only; 15 days of daily placebo, only) administered across two 15-day dosing periods (Period 1 and Period 2). The dosing periods will be separated by a 27-day washout. Participants will be randomized to a sequence of receiving IW-6463 for Period 1 and then placebo for Period 2, or vice versa.

02

Conditions studied

  • Other
03

In context

Lead sponsor

Tisento Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an ambulatory adult at least 65 years old at the screening visit
  • Subject is in good health and has no findings on physical examination
  • Female participants must be . A postmenopausal state is defined as no menses for ≥12 consecutive months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level at screening (>40 IU/L or mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state.
  • Male participants who have not been surgically sterilized by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) must agree use per protocol
  • Men must also agree to not donate sperm throughout the study and for 3 months after the final dose of study drug
  • Other inclusion criteria per protocol

Exclusion criteria

Exclusion Criteria:

  • Any active or unstable medical condition
  • Other exclusion criteria per protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IW-6463

    IW-6463 tablets administered orally

    Drug: IW-6463

  • Placebo comparator
    Placebo

    Matching placebo tablets administered orally

    Drug: Matching Placebo

Interventions

  • IW-6463 Tablet

    Also known as: CY6463, zagociguat

  • DrugMatching Placebo

    Matching Placebo Tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cerebral Blood Flow (CBF) at Day 15

    Change from baseline in CBF as measured by magnetic resonance imaging (MRI) and arterial spin labeling (ASL) after administration of IW-6463 vs. placebo

    Time frame: Baseline, 15 days

  2. Number of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 42 days

07

Study locations

1 site
  • Centre for Human Drug Research (CHDR)
    Leiden, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in May 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2020
First posted
Jan 27, 2020
StartActual
Jan 6, 2020
Primary completionActual
May 22, 2020
CompletionActual
May 22, 2020
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04240158
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Jan 6, 2020
Primary completion
May 22, 2020
Completion
May 22, 2020
Last update
Aug 16, 2024

Study contacts

Chad Glasser, PharmD
study director · Cyclerion Therapeutics, Inc
Geert Jan Groeneveld, MSc
principal investigator · Centre for Human Drug Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion